Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in Advanced Laryngeal Cancer
- 1 April 2008
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 134 (4), 363-9
- https://doi.org/10.1001/archotol.134.4.363
Abstract
To assess tumor markers in advanced laryngeal cancer. Marker expression and clinical outcome. Pretreatment tumor biopsy specimens were analyzed from patients enrolled in the Department of Veterans Affairs Laryngeal Cancer Study. Expression of p53 (OMIM TP53) and Bcl-xL (OMIM 600039) in pretreatment biopsy specimens was assessed for correlation with chemotherapy response, laryngeal preservation, and survival. Higher rates of larynx preservation were observed in patients whose tumors expressed p53 vs those that did not (80% [36 of 45 patients] vs 59% [24 of 41 patients], P =.03). Higher rates of larynx preservation were also observed in patients whose tumors expressed low levels of Bcl-xL vs high levels of Bcl-xL (90% [18 of 20 patients] vs 60% [30 of 50 patients], P =.02). Patients were categorized into 3 risk groups (low, intermediate, and high) based on their tumor p53 and Bcl-xL expression status. Patients whose tumors had the high-risk biomarker profile (low p53 expression and high Bcl-xL expression) were less likely to preserve their larynx than patients whose tumors had the intermediate-risk biomarker profile (high p53 expression and low or high Bcl-xL expression) or the low-risk biomarker profile (low p53 expression and low Bcl-xL expression). The larynx preservation rates were 100% (10 of 10 patients), 77% (26 of 34 patients), and 54% (7 of 13 patients) for the low-risk, intermediate-risk, and high-risk groups, respectively (P =.04, Fisher exact test). Tumor expression of p53 and Bcl-xL is a strong predictor of successful larynx preservation in patients treated with induction chemotherapy and followed by radiation therapy in responding tumors.Keywords
This publication has 30 references indexed in Scilit:
- Comparison of p16INK4a expression with p53 alterations in head and neck cancer by tissue microarray analysisThe Journal of Pathology, 2006
- P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma linesHead & Neck, 2003
- p53 and Cyclin D1 as Prognostic Factors in Squamous Cell Carcinoma of the LarynxThe Laryngoscope, 2003
- Nuclear and cytoplasmic p53 expression in pharyngeal squamous cell carcinoma: Prognostic implicationsHead & Neck, 2002
- Tumor Angiogenesis as a Predictive Marker for Organ Preservation in Patients With Advanced Laryngeal CarcinomaThe Laryngoscope, 2002
- Expression of Bcl‐2 Family Proteins in Advanced Laryngeal Squamous Cell Carcinoma: Correlation With Response to Chemotherapy and Organ PreservationThe Laryngoscope, 2002
- Cyclin D1 Overexpression versus Response to Induction Chemotherapy in Squamous Cell Carcinoma of the Head and Neck—Preliminary ReportActa Oncologica, 2001
- Prognostic significance of Bcl-2 and p53 expression in advanced laryngeal squamous cell carcinoma.Head & Neck, 2001
- Gain-of-function mutations in the tumor suppressor gene p53.2000
- p53 Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and NeckJournal of Clinical Oncology, 2000